display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
breast cancer - adjuvantbreast cancer - HER2-positivebreast cancer - HR positive
breast cancer - adjuvantes-BC - HER2 positive - (neo)adjuvant (NA)la/mBC - HER2 positive - 1st Line (L1)la/mBC - HER2 positive - 2nd Line (L2)la/mBC - HR-positive - 1st line (L1)
HER inhibitor
EGFR inhibitor
afatinib based treatment
afatinib plus vinorelbine LUX-Breast 1
HER2 inhibitor
neratinib based treatment
neratinib ExteNET ExteNET
neratinib plus capecitabine NALA NALA ...
pertuzumab based treatment
pertuzumab plus trastuzumab APHINITY PERTAIN
pertuzumab plus trastuzumab plus docetaxel CLEOPATRA PUFFIN
trastuzumab based treatment
docetaxel plus carboplatin with trastuzumab followed by trastuzumab BCIRG-006 ...
doxorubicin plus cyclophosphamide followed by docetaxel plus trastuzumab BCIRG-006 ... BCIRG-006 ...
trastuzumab plus endocrine therapy SYSUCC-002 SYSUCC-002
trastuzumab plus epirubicin and cyclophosphamide followed by docetaxel GeparQuinto
tucatinib based treatment
tucatinib plus trastuzumab plus capecitabine HER2CLIMB HER2CLIMB ...
TKI anti HER1/EGFR and HER2/neu
lapatinib based treatment
lapatinib plus capecitabine WJOG6110B/ELTOP
lapatinib plus fulvestrant CALGB 40302
lapatinib plus letrozole EGF30008 ... EGF30008 ...
lapatinib plus trastuzumab EGF104900

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons